Multicenter Study on the Long-Term (3-Year) Efficacy of Lanthanum Carbonate in Dialysis Patients

被引：0

作者：

Ando, Ryoichi ^{[1
]}

Yama, Satomi ^{[1
]}

Ohnishi, Tsuyoshi ^{[1
]}

Iwamoto, Shunsuke ^{[1
]}

Kimura, Hitoshi ^{[1
]}

Chida, Yoshiko ^{[2
]}

Ishida, Yuji ^{[3
]}

Yamada, Kouei ^{[4
]}

Inagaki, Yuichiro ^{[4
]}

Takayama, Masanobu ^{[5
]}

Tachibana, Ken ^{[6
]}

Kikuchi, Kan ^{[7
]}

Inoue, Atsushi ^{[7
]}

Ohtsuka, Masakazu ^{[8
]}

机构：

[1] Musashino Red Cross Hosp, Dept Nephrol, Tokyo, Japan

[2] Nakano Clin, Tokyo, Japan

[3] Kyonan Clin, Tokyo, Japan

[4] Kichijoji Ekimae Clin, Tokyo, Japan

[5] Takayama Clin, Tokyo, Japan

[6] Tachibana Clin, Tokyo, Japan

[7] Shimo Ochiai Clin, Tokyo, Japan

[8] Tokiwa Clin, Toride, Ibaraki, Japan

来源：

THERAPEUTIC APHERESIS AND DIALYSIS | 2014年 / 18卷

关键词：

Lanthanum Carbonate; Long-Term Effects; Management Target Values; Multicenter Study; CHRONIC KIDNEY-DISEASE; MORTALITY RISK; SERUM-CALCIUM; HEMODIALYSIS-PATIENTS; PHOSPHATE; HYPERPHOSPHATEMIA; PTH;

D O I：

10.1111/1744-9987.12206

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We previously conducted a multicenter study enrolling 101 dialysis patients with hyperphosphatemia in which lanthanum carbonate (LC) was administered for 2 years. In this study, the administration has been continued for an additional year, and we have evaluated the long-term (a total of 3 years) effects of LC. The average serum phosphorus (P) level was 6.05 mg/dL at the start and decreased to 5.84 mg/dL after 3 years, but no significant differences were observed at both points. The average serum corrected calcium (Ca) level significantly reduced after 3 years (P < 0.001). As results of evaluating the achievement rates with the management target values of serum P, Ca and intact parathyroid hormone (PTH) stated in the Japanese guideline, the achievement rates increased after 3 years. From these results, LC is considered to be a useful P binder that can be used for long-term treatment of hyperphosphatemia, without causing a Ca load.

引用

页码：2 / 8

页数：7

共 50 条

[21] Long-Term Outcomes of Implanon in Managing Adenomyosis: A 3-Year Prospective Study
Liao, Na
Wang, Lie
Mu, Hongxin
Qi, Qiwei
MEDICAL SCIENCE MONITOR, 2025, 31
[22] BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY
Van der Heijde, D.
Deodhar, A.
Gensler, L. S.
Poddubnyy, D.
Kivitz, A.
Dougados, M.
De Peyrecave, N.
Oortgiesen, M.
Vaux, T.
Fleurinck, C.
Baraliakos, X.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 332 - 333
[23] Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study
Takahiko Saida
Yasuto Itoyama
Seiji Kikuchi
Qi Hao
Takayoshi Kurosawa
Kengo Ueda
Lixin Zhang Auberson
Isao Tsumiyama
Kazuo Nagato
Jun-ichi Kira
BMC Neurology, 17
[24] Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study
Saida, Takahiko
Itoyama, Yasuto
Kikuchi, Seiji
Hao, Qi
Kurosawa, Takayoshi
Ueda, Kengo
Auberson, Lixin Zhang
Tsumiyama, Isao
Nagato, Kazuo
Kira, Jun-ichi
BMC NEUROLOGY, 2017, 17
[25] The long-term mortality of spontaneous bacterial peritonitis in cirrhotic patients: A 3-year nationwide cohort study
Hung, Tsung-Hsing
Tsai, Chen-Chi
Hsieh, Yu-Hsi
Tsai, Chih-Chun
TURKISH JOURNAL OF GASTROENTEROLOGY, 2015, 26 (02): : 159 - 162
[26] Study of Prolonged Administration of Lanthanum Carbonate in Dialysis Patients
Gotoh, Junichi
Kukita, Kazutaka
Tsuchihashi, Seiichiro
Hattori, Masahiro
Iida, Junichi
Horie, Takashi
Onodera, Kazuhiko
Furui, Hidenori
Tamaki, Toru
Meguro, Junichi
Yonekawa, Motoki
Kawamura, Akio
THERAPEUTIC APHERESIS AND DIALYSIS, 2013, 17 : 9 - 14
[27] Long-term spinal mobility in patients with ankylosin spondylitis (AS) -: 3-year results from the adalimumab (HUMIRA®) trial valuating long-term efficacy and safety in AS (ATLAS)
van der Heijde, Desiree
Schiff, Michael
Sieper, Joachim
Kivitz, Alan
Dijkmans, Ben
Mease, Philip
Kupper, Hartmut
Ballal, Shaila
Wong, Robert
ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S578 - S579
[28] SAFETY AND TOLERABILITY OF LONG-TERM TREATMENT WITH LANTHANUM CARBONATE
Siami, Ghodrat
Backs, Wolfgang
NEPHROLOGY, 2005, 10 : A297 - A297
[29] Maintained safety, tolerability and efficacy of lanthanum carbonate (Fosrenol®) during long-term therapy in hemodialysis patients.
Hutchison, A
Webster, I
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 764A - 764A
[30] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 1 STUDY
Mcinnes, I.
Kato, K.
Magrey, M.
Merola, J. F.
Kishimoto, M.
Haaland, D.
Li, Y.
Liu, Y.
Liu, J.
Lippe, R.
Wung, P.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1137 - 1138

← 1 2 3 4 5 →